Jubilant, Novavax Enter COVID-19 Vaccine Partnership

By Tim Wright, Editor, Contract Pharma | 03.29.21

Jubilant to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373.

Jubilant HollisterStier LLC, a wholly owned subsidiary of Jubilant Pharma Limited, has entered into a non-exclusive manufacturing agreement with Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373. Under the terms of the agreement, Jubilant HollisterStier’s Spokane, WA facility has begun production activities of NVX-CoV2373 final drug product intended for commercial distribution in the U.S.